GlassScriptPhysician profile
Sandra Cyril
NPI 1184653271
$11,604.85
in general payments reported to CMS, 2019-2025
34 companies · $2,160 in 2025
The $2,160 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,290 · 2022: $2,931 · 2023: $2,247 · 2024: $2,977 · 2025: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,135 · Consulting Fee: $820 · Education: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,134.67 |
| Consulting Fee | $820.00 |
| Education | $428.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $1,925.46 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $1,556.97 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $1,418.34 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Pfizer INC. | $865.22 | 2021-2025 | |
| Janssen Biotech, INC. | $707.33 | 2021-2025 | Tremfya |
| Dermavant Sciences, INC. | $532.30 | 2023-2024 | Vtama |
| Journey Medical Corporation | $531.67 | 2021-2023 | |
| Abbvie INC. | $447.92 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $392.27 | 2021-2025 | Blu-U, Odomzo |
| Genzyme Corporation | $380.83 | 2021-2025 | |
| Ucb, INC. | $370.64 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $365.74 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $332.76 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $321.32 | 2021-2023 | Siliq |
| E.R. Squibb & Sons, L.L.C. | $231.95 | 2023-2025 | Sotyktu |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $212.15 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $185.74 | 2022-2025 | Dupixent, Libtayo |
| Organon LLC | $131.38 | 2025 | Vtama |
| Epi Health, LLC | $94.33 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.72 | 2023-2025 | Spevigo |
| Lilly USA, LLC | $71.98 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $69.99 | 2023 | |
| Almirall LLC | $66.96 | 2022-2025 | Klisyri |
| Amgen INC. | $41.45 | 2023-2024 | Otezla |
| Verrica Pharmaceuticals INC. | $40.97 | 2023-2024 | Ycanth |
| Convatec INC. | $40.70 | 2025 | |
| Kyowa Kirin, INC. | $27.12 | 2025 | |
| Vyne Pharmaceuticals INC. | $26.69 | 2021 | |
| Mayne Pharma Commercial LLC | $26.56 | 2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $25.03 | 2021-2022 | |
| Organogenesis INC. | $20.45 | 2025 | Cygnus Dual |
| Biofrontera INC. | $18.99 | 2024 | Rhodoled Xl, Xepi, Bf-Rhodoled |
| Helsinn Therapeutics (U.S.), INC. | $17.34 | 2024 | Valchlor |
| Krystal Biotech INC | $13.58 | 2024 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Cyril listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.